October 16, 2006 — The European Commission has approved pregabalin capsules for the treatment of central neuropathic pain associated with spinal cord injury, stroke, and multiple sclerosis; and ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous infliximab achieved greater clinical remission and endoscopic response rates compared with placebo ...

INCHEON, South Korea--(BUSINESS WIRE)--Today, Celltrion Healthcare announced two new data sets on the SC formulation of infliximab, Remsima ® (CT-P13) in IBD, at the European Crohn’s and Colitis ...

Please provide your email address to receive an email when new articles are posted on . Use of a second anti-TNF — IV or subcutaneous agent — resulted in early response and long-term remission among ...

Inflectra (infliximab-dyyb)* and Remicade (infliximab) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat similar autoimmune conditions. This ...

May 15, 2006 — Health Canada has approved a 500-mg tablet formulation of saquinavir mesylate that significantly reduces the daily pill count for patients with HIV; the European Commission has approved ...

TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM ...

Celltrion Testing Access Program Expands Availability of Therapeutic Drug Monitoring to Support Patient Transition to ...

Merck & Co. today said it has launched in the U.S. a biosimilar of Remicade ® (infliximab), the blockbuster immune-mediated inflammatory disorders treatment it markets outside the U.S., including ...

Avsola (infliximab-axxq) is a prescription drug that’s used to treat certain autoimmune conditions. Avsola can cause side effects that range from mild to serious. Examples include infections and ...